Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have received a consensus recommendation of “Moderate Buy” from the twenty-five brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twenty-three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $211.00.

Several research firms recently commented on INSM. Truist Financial cut their price target on Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Jefferies Financial Group assumed coverage on Insmed in a research note on Monday, March 16th. They issued a “buy” rating and a $228.00 target price for the company. Leerink Partners lifted their price target on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a report on Tuesday, March 24th. Guggenheim reissued a “buy” rating and set a $207.00 price target on shares of Insmed in a research report on Friday. Finally, Barclays upped their price objective on shares of Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st.

Insider Activity

In related news, COO Roger Adsett sold 2,370 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the transaction, the chief operating officer directly owned 98,603 shares in the company, valued at approximately $10,084,128.81. This represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 6,149 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $108.47, for a total value of $666,982.03. Following the completion of the transaction, the insider owned 41,613 shares of the company’s stock, valued at $4,513,762.11. The trade was a 12.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 65,289 shares of company stock valued at $7,334,073. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several large investors have recently modified their holdings of the business. CIBC Private Wealth Group LLC lifted its stake in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Insmed by 10.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 69 shares during the period. ORG Partners LLC increased its holdings in shares of Insmed by 12.7% in the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 74 shares during the period. Private Advisor Group LLC raised its position in Insmed by 1.8% in the 1st quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company’s stock valued at $777,000 after purchasing an additional 82 shares during the last quarter. Finally, Glenmede Trust Co. NA raised its position in Insmed by 5.4% in the 1st quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 98 shares during the last quarter.

Insmed Price Performance

INSM traded down $2.65 on Friday, reaching $115.61. 2,931,490 shares of the company’s stock were exchanged, compared to its average volume of 4,102,796. The stock has a market cap of $25.06 billion, a PE ratio of -20.11 and a beta of 0.78. Insmed has a twelve month low of $90.39 and a twelve month high of $212.75. The stock’s fifty day moving average price is $107.21 and its 200-day moving average price is $138.27. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same quarter in the prior year, the company earned ($1.42) EPS. Insmed’s revenue was up 229.7% compared to the same quarter last year. Sell-side analysts expect that Insmed will post -2.55 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.